Maybank Kim Eng just released an update w a target price of 40 cts.
1. expect healthy EPS growth for FY17E
2. ophthalmology operations in Malaysia continue to improve from higher patient volume
3. continue to explore M&A opportunities
Above are the main highlights. Pls refer to Maybank Kim Eng report for details.
Lately there is not much interest in the healthcare sector. It may be a good time to pick up some shares for long hold. ISEC remains my counter of choice primarily because of its strong balance sheet, low valuation relative to other healthcare counters n decent dividend yield. Profit for the 6 months has been encouraging ..
Another encouraging point is CEO/Director share purchase in the open market - see below:
Dr Wong - eFORM1_final.pdf
This is the 2nd share purchase.